Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada

MONTREAL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical...
11 hours ago
from: GlobeNewswire

Attention deficit hyperactivity disorder, Canada, Knight Therapeutics, Viloxazine